Structural Biology, Research Applications, and Human Safety Considerations

Evidence Tier: Preclinical Only (#B34700)

Introduction

↑ Back to contents

IGF-1 LR3, formally designated Long [Arg3] IGF-1, is a synthetic 83-amino-acid peptide engineered to enhance and extend the biological activity of insulin-like growth factor 1 (IGF-1). Unlike its parent molecule—human IGF-1 (also called somatomedin C)—which has a circulating half-life of approximately 15 minutes, IGF-1 LR3 demonstrates a functional half-life of 20–30 hours in preclinical systems. This dramatic pharmacokinetic difference stems from two critical structural modifications: an N-terminal extension of 13 amino acids and an arginine substitution at position 3 of the native sequence.

These modifications were introduced deliberately to reduce IGF-1 LR3’s binding affinity for IGF-binding proteins (IGFBPs)—a family of regulatory proteins that normally sequester native IGF-1 and limit its bioavailability. By circumventing IGFBP regulation, IGF-1 LR3 maintains higher free hormone concentrations for longer periods, amplifying downstream signaling through the Type 1 IGF receptor (IGF-1R). Originally developed as a research tool in the 1990s to study IGF-1 physiology at the cellular and animal level, IGF-1 LR3 was never intended for clinical development in humans. It has no FDA approval, no Phase I safety data, and no established human dosing.

Despite this preclinical origin, IGF-1 LR3 has become widely discussed in bodybuilding, strength-sport, and biohacking communities, often administered subcutaneously at doses ranging from 20 to 100 micrograms per day. The compound is prohibited by the World Anti-Doping Agency (WADA) under the class of peptide hormones and growth factors. This review synthesizes peer-reviewed literature on IGF-1 LR3’s mechanism, research applications, human safety considerations, and regulatory status—with particular emphasis on separating rigorous evidence from extrapolation and speculation.

What Is IGF-1 LR3?

↑ Back to contents

IGF-1 LR3 is a recombinant human insulin-like growth factor 1 analog—a genetically engineered protein designed to enhance the biological potency and duration of action of native IGF-1. The parent molecule, native IGF-1 (also known as somatomedin C or mecasermin when pharmaceutical-grade), is a 70-amino-acid peptide hormone produced primarily by the liver and local tissues. It plays central roles in skeletal muscle growth, bone metabolism, immune function, and metabolic regulation.

Native IGF-1 circulates in the bloodstream complexed to IGF-binding proteins—particularly IGFBP-3, which sequesters approximately 99% of circulating IGF-1. This binding serves a regulatory function: it extends IGF-1’s half-life from seconds to minutes, buffers IGF-1 availability, and facilitates transport. However, the IGFBP-bound state renders IGF-1 largely inaccessible to its receptor. Free IGF-1—perhaps 1% of total circulating IGF-1—is the bioactive fraction.

Structural Modifications

IGF-1 LR3 differs from native IGF-1 in two key ways:

1. N-terminal extension: Addition of 13 amino acids (MAPRGETSFSQH) to the N-terminus, making it 83 amino acids long instead of 70. This extension is derived from a species variant (rhesus macaque IGF-1) and was selected during analog development to reduce IGFBP binding.
2. Arginine substitution at position 3: The native sequence has a glutamic acid (Glu) at position 3; IGF-1 LR3 has an arginine (Arg). This substitution further reduces IGFBP affinity.

These modifications dramatically lower IGF-1 LR3’s affinity for IGF-binding proteins, particularly IGFBP-3 and IGFBP-5. The result is a peptide with a much higher proportion of free, bioavailable hormone—and consequently, a prolonged functional half-life.

Origins and Discovery

↑ Back to contents

IGF-1 LR3 was developed in the early-to-mid 1990s as part of rational peptide engineering efforts to create more potent and longer-acting IGF-1 analogs for research applications. Scientists recognized that native IGF-1’s extremely short half-life and tight IGFBP regulation limited its utility as a research tool: rapid clearance made it difficult to study sustained IGF-1 signaling in cell culture and animal models, and IGFBP sequestration complicated interpretation of dose–response relationships.

The modifications were informed by comparative IGF-1 sequences across species (particularly the N-terminal extension from rhesus macaque IGF-1) and by systematic exploration of amino acid substitutions known to reduce IGFBP affinity. The Arg3 substitution was identified through similar structure–activity relationship studies. The resulting analog—IGF-1 LR3—proved highly useful for studying IGF-1 biology in cell culture and animal models, particularly for examining the effects of sustained IGF-1 signaling on muscle growth, metabolism, and tissue remodeling.

Throughout the 1990s and 2000s, IGF-1 LR3 appeared in numerous peer-reviewed studies in animal models, including rodents and some non-human primates. It was synthesized and distributed by several commercial research chemical vendors and became a standard tool in academic and industrial IGF-1 research. However, it was never subjected to human clinical trials, toxicology studies, or regulatory review by any drug authority. The compound remained exclusively a research tool.

Beginning in the late 2000s and accelerating through the 2010s, IGF-1 LR3 migrated into non-research contexts—primarily through underground biotech communities, performance-enhancement circles, and later mainstream biohacking forums. Information about structure, purported effects, and self-administration protocols circulated through online communities, gradually building a non-clinical user base. Today, IGF-1 LR3 is obtainable through research chemical suppliers, unauthorized compounding pharmacies, and black-market channels, though its legal and medical status remains wholly preclinical and non-approved.

Mechanism of Action

↑ Back to contents

IGF-1 Receptor Signaling

Like native IGF-1, IGF-1 LR3 exerts its biological effects primarily by binding to the Type 1 IGF receptor (IGF-1R)—a receptor tyrosine kinase expressed on nearly all mammalian cell types. Binding of IGF-1 LR3 to IGF-1R initiates receptor autophosphorylation and triggers two major intracellular signaling cascades:

1. Phosphatidylinositol 3-kinase / Protein kinase B (PI3K/Akt) pathway: This pathway promotes cell survival, protein synthesis, glucose uptake, and metabolic anabolism. Akt phosphorylation leads to downstream activation of mTOR complex 1 (mTORC1), which is central to ribosomal protein synthesis and muscle growth. Akt also inhibits glycogen synthase kinase 3 beta (GSK3β) and FOXO transcription factors, reducing protein degradation and promoting anabolic processes.
2. Mitogen-activated protein kinase / Extracellular signal-regulated kinase (MAPK/ERK) pathway: This pathway activates through autophosphorylated IGF-1R recruiting growth factor receptor-bound protein 2 (Grb2) and Son of Sevenless (SOS), initiating a kinase cascade that culminates in ERK1/2 phosphorylation. ERK signaling promotes cell proliferation, differentiation, and gene expression changes associated with growth.

Both pathways converge on outcomes relevant to muscle growth: increased protein synthesis, suppressed proteolysis, enhanced glucose utilization, and proliferation of myogenic precursor cells. IGF-1 LR3 activates these pathways through the same mechanism as native IGF-1—they are pharmacologically equivalent at the receptor level.

Metabolic and Insulin-like Effects

IGF-1, including IGF-1 LR3, exhibits insulin-like activity because of structural homology to insulin and cross-reactivity with insulin receptors at high concentrations. IGF-1 LR3 can promote glucose uptake in peripheral tissues (muscle, adipose), enhance glycogen synthesis, and suppress hepatic glucose output. At physiological concentrations, this insulin-like activity is modest, but at high supraphysiological doses—as used in non-clinical settings—these effects become pronounced. This is a significant source of hypoglycemic risk, discussed in detail below.

Extended Half-life and Pharmacokinetics

The critical distinction between IGF-1 LR3 and native IGF-1 lies in pharmacokinetics. Native IGF-1 has a serum half-life of approximately 12–15 minutes because it is rapidly filtered by the kidneys and bound by IGFBPs, which sequester and transport it. IGF-1 LR3, by virtue of its reduced IGFBP binding affinity, circulates with a much larger free fraction. Preclinical studies in rodents and non-human primates suggest a functional half-life of approximately 20–30 hours—roughly 80–120 times longer than native IGF-1.

This extended half-life means that even modest daily doses can accumulate to create sustained, supraphysiological IGF-1 signaling. A single 50 mcg injection may persist at bioactive levels for one to two days, and repeated daily dosing rapidly achieves steady-state concentrations far above those achieved by endogenous IGF-1 production. This is both the intended research advantage (sustained signaling in animal models) and a major safety concern in humans (inability to rapidly reverse exposure if adverse events occur).

Key Research Areas

↑ Back to contents

Muscle Growth and Protein Synthesis

The majority of IGF-1 LR3 research has focused on its capacity to stimulate skeletal muscle growth in rodent models. Studies have demonstrated that IGF-1 LR3 administration to mice and rats increases muscle fiber cross-sectional area, promotes myogenic gene expression (including myogenin and muscle regulatory factor 4), and enhances protein synthesis via mTORC1 activation. Some work has examined site-specific injection of IGF-1 LR3 into muscle, which produces localized hypertrophy and can overcome age-related or disuse-induced muscle atrophy in aging models.

These findings are mechanistically sound—IGF-1 is unquestionably a powerful muscle-growth hormone—but animal models do not reliably predict human response. Rodents have vastly different metabolic rates, growth kinetics, and organ physiology than humans, and small animal studies rarely account for systemic side effects (organ hypertrophy, metabolic derangement) that might emerge at the supraphysiological doses required for muscle growth in larger species.

Metabolism and Lipogenesis

Several preclinical studies have examined IGF-1 LR3’s effects on glucose metabolism and fat oxidation. IGF-1 promotes glucose uptake and glycogen synthesis and, at high doses, suppresses hepatic gluconeogenesis. In rodents, IGF-1 LR3 administration can reduce body fat and improve insulin sensitivity—though these effects vary with dose, duration, and baseline metabolic status. Some work suggests IGF-1 signaling promotes lipid oxidation and mitochondrial biogenesis, particularly under caloric restriction.

Again, these preclinical findings suggest potential metabolic benefits, but human translation is uncertain. Rodent metabolism differs fundamentally from human metabolism (rodents have much higher metabolic rates and different thermoregulatory strategies), and the effects of sustained supraphysiological IGF-1 signaling on human lipid metabolism, insulin secretion, and pancreatic beta-cell function remain entirely unknown.

Tissue Repair and Regeneration

A secondary research area concerns IGF-1’s role in wound healing, tendon and bone repair, and recovery from tissue injury. IGF-1 promotes collagen synthesis, fibroblast proliferation, and angiogenesis—all relevant to tissue remodeling. Some animal studies have examined whether IGF-1 LR3 can accelerate recovery from muscle injury or promote bone healing. The data are preliminary and inconsistent, and no human trials have been conducted.

The theoretical appeal is evident—accelerated recovery from training or injury could benefit athletes—but the risk profile is unclear, particularly if the compound promotes fibrotic remodeling or pathological tissue growth in chronic use scenarios.

Metabolism in Aging Models

A smaller literature has explored IGF-1 LR3 as a potential countermeasure to age-related decline—particularly sarcopenia (age-related muscle loss). Some rodent studies show that IGF-1 LR3 can reverse age-induced muscle atrophy and improve strength. However, this work is limited, and the relevance to human aging is speculative. Additionally, sustained IGF-1 signaling throughout the lifespan has been associated with reduced longevity in some organisms (notably Caenorhabditis elegans and some rodent models), suggesting that boosting IGF-1 chronically might entail trade-offs in lifespan and cancer risk—an ironic contradiction for an anti-aging intervention.

Common Claims versus Current Evidence

↑ Back to contents

Human Evidence Landscape

↑ Back to contents

There are zero published human clinical trials of IGF-1 LR3. Not one. The compound has never entered Phase I, Phase II, or any other clinical development pathway. No regulatory agency—the FDA, EMA, PMDA, or any other—has ever reviewed IGF-1 LR3 for human use. No institutional review board (IRB) has approved its study in humans. No clinical safety data, pharmacokinetics in humans, dose–response relationships, or efficacy estimates exist in peer-reviewed literature.

All information about IGF-1 LR3 effects in humans is derived from:

1. Anecdotal reports: Online accounts from bodybuilders and biohackers describing subjective experiences, perceived muscle gains, and side effects. These reports are uncontrolled, lack biochemical verification, and are heavily biased toward those who survived adverse effects without serious injury.
2. Extrapolation from animal data: Inference that results from rodent or primate studies will translate to humans—an assumption that is frequently wrong.
3. Pharmacology of native IGF-1: Application of knowledge about mecasermin (pharmaceutical human IGF-1) to IGF-1 LR3, despite their different pharmacokinetics and IGFBP binding profiles.

This is not a gap that “more research will fill.” The absence of human data for a decades-old research compound strongly suggests that no sponsor (academic or commercial) has found sufficient signal of safety or efficacy to justify human trials, and no regulatory pathway exists for a non-therapeutic research chemical.

Safety, Risks, and Limitations

↑ Back to contents

Hypoglycemia and Metabolic Derangement

IGF-1 exerts powerful insulin-like effects: it promotes glucose uptake in peripheral tissues, suppresses hepatic glucose production, and enhances glycogen synthesis. In rodents and humans receiving supraphysiological doses of native IGF-1, hypoglycemia (low blood glucose) is a well-documented adverse effect. IGF-1 LR3, with its extended half-life and sustained bioavailability, would be expected to carry a similar or greater risk.

Hypoglycemia is dangerous, particularly when severe or prolonged. Symptoms include tremor, palpitations, sweating, confusion, and—at extreme levels—seizures, coma, and death. For an individual using IGF-1 LR3 without medical supervision or continuous glucose monitoring, the risk is elevated. Anecdotal reports from non-clinical users include episodes of symptomatic hypoglycemia, sometimes severe enough to require carbohydrate ingestion to reverse. The susceptibility to hypoglycemia varies dramatically between individuals based on baseline insulin sensitivity, diet, activity level, and genetic factors; there is no reliable way to predict individual risk.

Furthermore, prolonged IGF-1 signaling may impair endogenous glucose homeostasis, increasing basal insulin secretion and sensitizing individuals to hypoglycemic episodes over time. The notion that “eating carbohydrates” reliably prevents hypoglycemia is dangerous—hypoglycemia in sleep or during physical activity can occur unexpectedly, and chronic carbohydrate over-consumption to offset hypoglycemic risk would promote weight gain and metabolic dysfunction.

Cancer Risk and Cellular Proliferation

IGF-1 signaling is intimately involved in cell growth and proliferation. The IGF-1/IGF-1R axis is activated in many human cancers—including breast, prostate, colon, and lung cancers—where it promotes malignant cell proliferation, survival, and metastasis. Epidemiological studies in humans have found associations between elevated serum IGF-1 and risk of certain cancers, particularly prostate and breast cancer, though causality is debated and confounding factors are substantial.

The specific risk posed by IGF-1 LR3 in humans is unknown. However, sustained supraphysiological IGF-1 signaling—even at doses that individuals believe to be “modest”—would increase proliferative signaling in all IGF-1R-expressing cells, including pre-malignant and malignant cells. If an individual harbors occult malignancy or pre-cancerous lesions, IGF-1 LR3 could theoretically accelerate progression. This risk is not quantifiable without human studies, which do not exist. The duration required for increased cancer risk to manifest is also unknown—weeks, months, or years of exposure might be required, making surveillance difficult.

Importantly, IGF-1 LR3 cannot be recommended with informed consent regarding cancer risk because the risk itself cannot be quantified.

Organ Hypertrophy and Pathological Remodeling

Sustained IGF-1 signaling promotes growth not only in muscle but in all tissues. In rodents and non-human primates receiving chronic IGF-1 or growth hormone, organ hypertrophy—enlargement of the heart, liver, kidneys, and gastrointestinal tract—is well-documented. In humans with acromegaly (chronic growth hormone excess), similar organ hypertrophy occurs, including cardiomegaly (enlarged heart) and visceral organ growth, which contribute to morbidity and mortality.

In the bodybuilding community, high-dose growth hormone and IGF-1 axis stimulation have been associated with a distinctive phenotype of abdominal distension and visceral organ enlargement—colloquially termed “GH gut,” “palumboism,” or “insulin gut.” While the exact etiology is debated (growth hormone, insulin use, IGF-1, and poor diet all contribute), the condition reflects pathological organ remodeling. Chronic supraphysiological IGF-1 signaling likely plays a role.

The specific risk of IGF-1 LR3 for cardiac hypertrophy, cardiomyopathy, or other organ pathology in humans is unknown. Even if cardiac or organ effects are subclinical in the short term, chronic use could set the stage for late-life pathology (heart failure, organ dysfunction).

Acromegaly-like Syndrome

Chronic elevation of growth hormone and IGF-1 results in acromegaly—a syndrome characterized by facial coarsening, hand and foot enlargement, joint pain (arthralgia), carpal tunnel syndrome, diabetes, hypertension, and increased cardiovascular mortality. Although acromegaly is primarily a growth hormone disorder, IGF-1 elevation is the primary mediator of systemic effects. Individuals using high-dose growth hormone or IGF-1 analogs over extended periods sometimes develop acromegaly-like features: facial changes, hand swelling, and joint pain.

IGF-1 LR3 specifically could conceivably induce similar effects, though the evidence is speculative. The risk would increase with dose and duration of use. Again, without human studies, quantification is impossible.

Hypersensitivity and Immune Reactions

IGF-1 LR3 is a synthetic, non-endogenous peptide. While it is derived from the human IGF-1 sequence with small modifications, repeated subcutaneous injection in a non-clinical context (using non-sterile reagents from research chemical suppliers, improperly stored, or contaminated) carries risk of injection site reactions, infections, and potentially systemic immune responses. Sterility and pyrogenicity testing are not guaranteed for research chemicals obtained outside pharmaceutical supply chains.

Additionally, the N-terminal extension of IGF-1 LR3 is non-human in sequence; theoretically, chronic exposure could trigger anti-IGF-1 LR3 antibody formation, neutralizing the compound and potentially cross-reacting with endogenous IGF-1. The clinical significance of such antibodies is uncertain.

Injection Site Complications

Repeated subcutaneous or intramuscular injection—particularly at the doses and frequencies used in non-clinical settings—can lead to lipohypertrophy (local fat accumulation), injection site nodules, fibrosis, and sterile abscesses. Inadequate aseptic technique increases risk of localized or systemic infection. Cases of serious infection, including necrotizing soft tissue infections, have been associated with injection of non-pharmaceutical peptides in non-clinical contexts.

Long-Term and Irreversible Effects

Because IGF-1 LR3 has a functional half-life of 20–30 hours, it cannot be rapidly reversed if adverse events occur (unlike native IGF-1, which is cleared within minutes). Additionally, sustained IGF-1 signaling may trigger epigenetic and transcriptional changes that persist even after the hormone is cleared—for example, altered expression of genes involved in growth and metabolism might not fully normalize immediately upon cessation of dosing.

Some organ changes (particularly cardiac hypertrophy) may be irreversible. If an individual develops cardiomegaly or other serious pathology, stopping the compound may not reverse the damage.

Legal and Regulatory Status

↑ Back to contents

FDA Status

IGF-1 LR3 is not approved by the FDA for any indication in any population. It is not an investigational new drug (IND) under FDA oversight, and no clinical trial applications for IGF-1 LR3 have been submitted to the FDA in decades (if ever). The FDA has not reviewed IGF-1 LR3’s chemistry, manufacturing, and controls (CMC), and no pharmaceutical manufacturer has obtained FDA approval to produce IGF-1 LR3 as a therapeutic.

Conversely, mecasermin (Increlex, Iplex)—which is pharmaceutical-grade recombinant human IGF-1—is FDA-approved for a narrow indication: severe primary IGF-1 deficiency in growth-retarded children and adolescents with mutations in the IGF-1 gene or related genetic disorders. Mecasermin is a native IGF-1 molecule, not an analog, and has undergone full clinical development with Phase I, II, and III trials. Its pharmacokinetics, safety, and efficacy in this narrow population are established. However, mecasermin is not approved for athletic performance, bodybuilding, or any indication in healthy individuals.

IGF-1 LR3 is not the same as mecasermin. The structural differences—the N-terminal extension and Arg3 substitution—fundamentally alter pharmacokinetics and tissue distribution. Data from mecasermin trials cannot be directly applied to IGF-1 LR3, and the longer half-life and reduced IGFBP binding of IGF-1 LR3 suggest a different, likely broader, risk profile.

Under FDA law, manufacturing, distributing, and possessing unapproved drugs is illegal. However, IGF-1 LR3 is often sold under the label “not for human consumption” by research chemical suppliers, which functions as a de facto legal workaround—the supplier claims no intent for human use, even though the purchaser may intend such use. This labeling does not confer legal immunity to the purchaser, and there is no clear legal safe harbor for obtaining or using non-pharmaceutical IGF-1 LR3 in the United States.

WADA and Sports Regulation

IGF-1 LR3 is prohibited by the World Anti-Doping Agency (WADA) under the Prohibited List, Class S2 (Peptide Hormones, Growth Factors, and Related Substances). This classification includes all growth factors, including IGF-1 and all IGF-1 analogs, whether endogenous or synthetic. Athletes subject to WADA rules—including competitive bodybuilders, powerlifters, and participants in any sport under Olympic or international federation governance—cannot legally use IGF-1 LR3.

Testing for IGF-1 LR3 is challenging because the molecule is not uniquely identifiable from native IGF-1 using standard mass spectrometry (both have the same amino acid sequence, albeit with different N-terminal extensions). However, the extended N-terminus can be detected via high-resolution proteomics or sequencing. Some anti-doping laboratories employ peptide sequencing to distinguish IGF-1 LR3 from native IGF-1.

DEA and Controlled Substance Status

IGF-1 LR3 is not a scheduled controlled substance under the Drug Enforcement Administration (DEA). It is not a small-molecule drug and is not listed on the DEA’s list of controlled substances. However, this does not mean it is legal to manufacture, distribute, or possess. It remains an unapproved drug under FDA jurisdiction.

International Status

Regulatory status varies by country. In most developed nations (Canada, UK, Australia, EU member states), IGF-1 LR3 is not approved for human use and falls under the regulatory purview of national drug authorities. Manufacture and distribution are illegal without authorization; possession for personal use exists in a legal gray zone (some jurisdictions prosecute, others do not).

In some countries, particularly those with less stringent pharmaceutical regulation, IGF-1 LR3 may be obtainable through licensed pharmacies without prescription, though this does not indicate safety approval—it reflects regulatory gaps.

Research Protocols

↑ Back to contents

This section summarizes the methodology and dosing of published preclinical studies of IGF-1 LR3, to contextualize the research evidence and highlight gaps relevant to potential human extrapolation.

Rodent Muscle Growth Studies

Model organism: Mice and rats (C57BL/6, Sprague-Dawley strains most common). Route: Intraperitoneal or subcutaneous injection. Dose range: Typically 5–50 mcg/kg body weight (rodents), delivering micrograms to low tens of micrograms per animal per day. Duration: 2–8 weeks (short-term); few studies exceed 12 weeks. Outcomes: Muscle weight, fiber cross-sectional area, grip strength (occasionally), protein synthesis rates (via radiolabeling or phospho-protein assays), myogenic gene expression (qPCR).

Key limitation: Rodent physiology differs vastly from human physiology. Rodents have metabolic rates ~5–10 times higher than humans (per unit body weight), shorter lifespans, and different organ sensitivity to growth factors. A dose considered “moderate” in a mouse study would translate to a much higher dose per kilogram in humans—extrapolation is fraught with error.

Non-Human Primate Studies

Model organism: Macaques and other primates (more closely related to humans). Route: Intravenous or subcutaneous injection. Dose range: Typically 1–10 mcg/kg; fewer studies, generally smaller sample sizes. Duration: 2–12 weeks. Outcomes: Muscle mass, metabolic markers, organ histology (occasionally).

Key advantage: Primates have physiology more similar to humans, and dose scaling to humans is more reasonable. Key limitation: Few primate studies of IGF-1 LR3 have been published; much more data exist for native IGF-1 or growth hormone. Primate studies are expensive and ethically sensitive, limiting their extent. Long-term chronic studies (years of treatment) are rare.

Age-Related Muscle Loss Models

Model: Aged rodents (>18–24 months old) or muscle-atrophy models (immobilization, denervation, or disuse in younger animals). Intervention: IGF-1 LR3 or native IGF-1 injection. Outcomes: Reversal of atrophy, recovery of fiber size and strength.

Finding: IGF-1 administration (both native and LR3) partially reverses age-related muscle atrophy in rodents, particularly if combined with exercise. However, chronic IGF-1 elevation in aging organisms has shown mixed effects on lifespan and disease burden—some studies suggest shortened lifespan from sustained growth factor elevation.

Tissue Repair and Wound Healing

Model: Muscle injury (crush, laceration, denervation), bone fracture, or skin wound. Intervention: Local or systemic IGF-1 LR3. Outcomes: Healing speed, scar tissue formation, strength recovery.

Status: Limited data; mixed results. Some studies show accelerated healing; others show excessive fibrotic scar formation. Long-term outcomes (months to years post-injury) are rarely examined.

Dosing in Published Research

↑ Back to contents

Dose Scaling Considerations

Converting rodent doses to human-equivalent doses is a common source of error. The standard approach uses allometric scaling based on body surface area (BSA) or body weight, with adjustments for metabolic rate. A rough approximation:

Human equivalent dose ≈ (Animal dose in mg/kg) × (Animal weight in kg / Human weight in kg)^(1/3)

For a 50 mcg/kg dose in a 25 g mouse (0.025 kg):

Mouse dose = 50 mcg/kg × 0.025 kg = 1.25 mcg total

Human scaling to 70 kg = 50 mcg/kg × (0.025/70)^(1/3) ≈ 50 mcg/kg × 0.089 ≈ 4.5 mcg/kg for a 70 kg human ≈ 315 mcg

This rough calculation suggests that rodent doses producing clear muscle growth (50 mcg/kg) scale to approximately 300+ mcg in humans using conservative allometric methods. However, such scaling assumes equivalent pharmacodynamics, which is not guaranteed. Rodents may be more or less sensitive than humans to IGF-1 LR3. The scaling becomes even more uncertain for toxicity and adverse effects—a compound tolerated at high rodent doses may be dangerously toxic in humans, or vice versa.

Dosing in Self-Experimentation

↑ Back to contents

Comparison to Published Research Doses

Non-clinical doses reported in online communities (20–100 mcg/day) are often presented as “low” or “conservative.” However, comparing to published research is instructive:

• A 50 mcg/day dose in a 70 kg human = 0.71 mcg/kg/day.
• Rodent studies producing robust muscle growth use 10–50 mcg/kg/day—10–70 times higher per kilogram.
• However, rodent and human sensitivity to IGF-1 may differ; allometric scaling has error margins of 2–5 fold or more.
• Thus, 50 mcg/day in a human could represent either a sub-active dose (if humans are less sensitive) or a supraphysiologically high dose (if humans are more sensitive).

The bottom line: there is no scientific basis for recommending any dose of IGF-1 LR3 in humans. Underground protocols are based on trial-and-error, anecdote, and extrapolation from research chemical knowledge, not from human pharmacology.

Frequently Asked Questions

↑ Back to contents

Related Peptides and Comparisons

↑ Back to contents

IGF-1 DES (Insulin-like Growth Factor 1 Des(1-3))

Structure: Native human IGF-1 with the first three amino acids (Phe-Phe-Tyr) deleted. IGFBP affinity: ~10-fold lower than native IGF-1, but higher than IGF-1 LR3. Half-life: Approximately 5–10 hours (longer than native IGF-1, shorter than IGF-1 LR3). Mechanism: IGF-1R activation; similar to IGF-1 and IGF-1 LR3, but perhaps with relatively greater preference for insulin-like metabolic effects and less pronounced mitogenic activity. Evidence: Limited preclinical studies; essentially no human data. Reported use: Post-workout injection or localized injection; believed to have less cancer risk than IGF-1 LR3 (speculative). WADA status: Prohibited under S2 (as an IGF-1 analog).

Comparison to IGF-1 LR3: IGF-1 DES has a shorter half-life and may cause less sustained proliferative signaling. However, evidence for superiority in terms of safety or efficacy is absent. Both are non-approved research compounds with minimal human data.

Mechano Growth Factor (MGF / IGF-1 Ec)

Structure: A splice variant of IGF-1 mRNA that produces a 24-amino-acid N-terminal extension, distinct from IGF-1 LR3’s extension. Function: Local paracrine signaling; promotes myogenic cell proliferation and differentiation in response to mechanical stimulus (exercise). Half-life: Very short (minutes); rapidly inactivated by proteolysis. Mechanism: IGF-1R signaling, but may have unique cellular actions distinct from systemic IGF-1. Evidence: Preclinical studies showing local muscle growth and repair after injury; very limited evidence. Reported use: Post-workout injection or local injection into muscles. WADA status: Prohibited (as a growth factor analog).

Comparison to IGF-1 LR3: MGF is endogenous (produced locally during exercise) and has a much shorter half-life, suggesting lower systemic risk. However, exogenous MGF administration in non-clinical settings is also non-approved and has virtually no human safety data. The theoretical advantage of MGF’s short half-life is appealing but unproven.

Native Human IGF-1 (Mecasermin, Increlex, Iplex)

Status: FDA-approved for severe primary IGF-1 deficiency (growth hormone-insensitive dwarfism) in children and adolescents. Half-life: 12–15 minutes (unmodified). IGFBP binding: High; ~99% bound to IGFBP-3. Efficacy in deficiency: Promotes linear growth and metabolic improvement in genetically IGF-1-deficient children. Safety profile: Documented through clinical trials; risks include hypoglycemia (especially in young children), benign intracranial hypertension, and potential long-term effects on bone and metabolism.

Comparison to IGF-1 LR3: Mecasermin is approved and has clinical trial data, but only for a narrow pediatric indication. Its safety profile at high doses or in healthy adults is not established. IGF-1 LR3’s pharmacokinetics are so different that mecasermin data do not directly inform IGF-1 LR3 safety. Mecasermin is expensive, rarely available outside the pediatric deficiency context, and not used in bodybuilding. IGF-1 LR3 is a research analog without clinical approval.

Growth Hormone (GH / Somatropin)

Status: FDA-approved for growth hormone deficiency in children and adults, and several other indications (short stature, HIV-associated wasting). Mechanism: GH works partly through direct effects and partly through IGF-1 (GH stimulates hepatic and local IGF-1 production). Half-life: ~15–30 minutes (shorter than IGF-1 LR3, but longer than native IGF-1). Overlap with IGF-1 LR3: Both promote muscle growth; GH effects on metabolism and body composition are partially mediated through IGF-1. Safety in approved indications: Well-characterized; risks include metabolic abnormalities, carpal tunnel, arthralgia, acromegaly-like changes. Safety in healthy adults: Increased cancer risk, insulin resistance, and cardiovascular pathology are concerns based on some epidemiological evidence.

Comparison to IGF-1 LR3: GH is approved for specific indications and has decades of clinical experience, but safety in healthy athletes is not established. IGF-1 LR3 is not approved for any indication. If anything, IGF-1 LR3 (with its prolonged half-life and sustained signaling) carries a potentially higher risk profile than GH. They are often stacked in non-clinical bodybuilding (GH + IGF-1 LR3), compounding risk.

Summary

↑ Back to contents

IGF-1 LR3 is a synthetic analog of human IGF-1 engineered to overcome natural bioavailability limitations. Its N-terminal extension and Arg3 substitution drastically reduce binding to IGF-binding proteins, resulting in a ~20–30 hour functional half-life compared to ~15 minutes for native IGF-1. This extended pharmacokinetic profile made it a valuable research tool for studying sustained IGF-1 signaling in cell culture and animal models, where it was originally developed in the 1990s.

IGF-1 LR3 has never been tested in humans under controlled conditions. No clinical trials have been conducted, no regulatory agency has reviewed it for safety or efficacy, and no pharmaceutical manufacturer produces it as an approved therapeutic. All information about its effects in humans is anecdotal, speculative, or extrapolated from animal data—none of which constitutes reliable evidence for human use.

The mechanism is well-understood: IGF-1 LR3 activates the Type 1 IGF receptor, triggering PI3K/Akt and MAPK/ERK signaling cascades that promote cell growth, protein synthesis, and glucose utilization. These are the same pathways activated by native IGF-1 and growth hormone. However, mechanism ≠ safety or efficacy. Robust mechanisms can produce dangerous compounds.

The documented preclinical evidence supports muscle growth in rodents and some non-human primates, consistent with IGF-1 biology. However, animal models are poor predictors of human response. Rodent physiology, metabolism, and tissue sensitivity differ vastly from humans. Dose scaling is uncertain by 2–5 fold or more. Most critically, long-term systemic effects in humans are entirely unknown.

The safety risks are substantial and incompletely quantifiable:

• Hypoglycemia: Severe, unpredictable, and potentially life-threatening. Individual susceptibility is highly variable, and dietary countermeasures are unreliable.
• Cancer risk: Sustained IGF-1 signaling is associated with increased cellular proliferation and has epidemiological links to certain cancers. The specific risk posed by IGF-1 LR3 in humans is unknowable without human studies.
• Organ hypertrophy: Cardiomegaly, hepatomegaly, and visceral organ enlargement are documented in chronic acromegaly and animal models of prolonged IGF-1 elevation. IGF-1 LR3 could trigger similar pathology.
• Acromegaly-like syndrome: Facial coarsening, hand/foot enlargement, arthralgia, and metabolic dysfunction are possible with prolonged exposure.
• Injection-site complications: Infection, lipohypertrophy, and sterile abscesses from repeated non-pharmaceutical injection.
• Irreversibility: Some effects—particularly organ hypertrophy—may not reverse even after cessation of dosing.

The legal status is clear: IGF-1 LR3 is not FDA-approved, not in clinical development, and not authorized for human use anywhere. It is prohibited by WADA. It is often sold under “not for human consumption” labels, which do not confer legal immunity. Individuals who obtain and use IGF-1 LR3 are in violation of federal law (unapproved drug) and do so entirely outside any regulatory framework or medical supervision.

The practical reality: IGF-1 LR3 has become a fixture in underground bodybuilding and biohacking communities, used at doses (20–100 mcg/day) that are neither scientifically justified nor safely monitored. Users are essentially conducting an uncontrolled human experiment on themselves, with unknown outcomes, no ability to predict individual risk, and no rapid means of reversing adverse events.

Honest assessment: IGF-1 LR3 is not a therapy. It is not a supplement. It is not a research compound for personal use—it was designed for laboratory and animal research only. Using it to enhance muscle growth is using a preclinical research tool in a human population for which any safety and efficacy data are absent. The risks—hypoglycemia, cancer, organ damage, irreversible pathology—are serious and cannot be quantified or reliably managed without human clinical study, which does not exist and is unlikely to occur.

If considering IGF-1 LR3 use, the honest Dutch Uncle assessment is this: You are volunteering for an uncontrolled, unmeasured human experiment. You will receive modest muscle growth, potentially substantial systemic effects you cannot predict or rapidly reverse, legal liability, and zero medical support or monitoring. Better options exist: progressive resistance training, adequate protein, sleep, and if desired, approved performance-enhancement compounds with established risk profiles (though all carry risks, and none are recommended outside legitimate medical contexts).

References

↑ Back to contents

Further Reading

↑ Back to contents

• Fundamental IGF-1 physiology: Roith DL, Scavo LM, Grago SL. Pathophysiology of growth hormone and insulin-like growth factor I deficiency. Endocrinol Metab Clin North Am. 1992;21(3):481–517. — Comprehensive review of native IGF-1 biology, signaling, and physiological roles.
• Muscle growth and mechanotransduction: Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3(11):1014–1019. — Details the downstream signaling of IGF-1R activation in muscle.
• IGF-1 and cancer: Giustina A, Ambrosio MR, Bondanelli M, et al. Growth hormone, insulin-like growth factor-I, and cancer. J Endocrinol Invest. 2014;37(3):285–298. — Reviews epidemiology and mechanistic links between IGF-1 elevation and malignancy.
• Acromegaly and organ pathology: Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951. — Clinical presentation and organ complications of chronic growth hormone and IGF-1 excess.
• WADA Prohibited List and testing: WADA Technical Document—Biomarker Passport. World Anti-Doping Agency; 2023. — Information on how anti-doping organizations detect prohibited peptides and growth factors.
• Regulatory framework for unapproved drugs: FDA. Guidance for Industry: Importing Drug Products into the United States. 2009. — Overview of FDA legal authority regarding unapproved drug products.

Disclaimer

↑ Back to contents

Article published by Peptidings Research & Editorial Board
Evidence tier: Preclinical Only. Updated March 2026.
This is a living document; updates will reflect emerging evidence.